DETECTING RECURRENT OR RESIDUAL LUNG-CANCER WITH FDG-PET

被引:0
|
作者
INOUE, T
KIM, EE
KOMAKI, R
WONG, FCL
BASSA, P
WONG, WH
YANG, DJ
ENDO, K
PODOLOFF, DA
机构
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NUCL MED,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT RADIOTHERAPY,HOUSTON,TX 77030
[3] GUNMA UNIV,SCH MED,DEPT NUCL MED,MAEBASHI,GUMMA 371,JAPAN
[4] UNIV BARCELONA,HOSP CLIN BARCELONA,SCH MED,DEPT NUCL MED,BARCELONA,SPAIN
关键词
POSITRON EMISSION TOMOGRAPHY; FLUORODEOXYGLUCOSE; LUNG CANCER; RECURRENT LUNG CANCER;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We investigated the diagnostic accuracy of FDG-PET in the detection of recurrent lung cancer. Methods: Thirty-nine lesions in 38 patients with clinically suspected recurrent or residual lung cancer were studied with PET. All PET images were visually interpreted in conjunction with thoracic CT or MRI. Semiquatititative analysis using standardized uptake values (SUVs) was also performed in 25 lesions. FDG-PET diagnoses were correlated with pathological diagnoses and clinical outcome. Results: The sensitivity and specificity of FDG-PET for detecting recurrent tumors were 100% (26/26) and 61.5% (8/13), respectively. The difference in mean SUV between recurrent tumors and noncancerous lesions was statistically significant [11.2 +/- 5.7 (n = 16)vs. 3.5 +/- 1.8 (n = 9), p < 0.0001]. False-positive results showed relatively lower SUVs than true-positives and also demonstrated increased uptake in a curvilinear rather than nodular shape. Conclusion: FDG-PET is useful for detecting recurrent lung cancer after treatment. False-positive diagnoses might be reduced by analysis of uptake shape and serial changes in SUV, but further study is needed.
引用
收藏
页码:788 / 793
页数:6
相关论文
共 50 条
  • [1] Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer
    Bury, T
    Corhay, JL
    Duysinx, B
    Daenen, F
    Ghaye, B
    Barthelemy, N
    Rigo, P
    Bartsch, P
    EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (06) : 1376 - 1380
  • [2] Limitations of FDG-PET and FDG-PET With Computed Tomography for Detecting Synchronous Cancer in Pharyngeal Cancer
    Suzuki, Hidenori
    Hasegawa, Yasuhisa
    Terada, Akihiro
    Ogawa, Tetsuya
    Hyodo, Ikuo
    Suzuki, Masahiro
    Nakashima, Tsutomu
    Tamaki, Tsuneo
    Nishio, Masami
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2008, 134 (11) : 1191 - 1195
  • [3] Evaluation of residual or recurrent malignant lymphoma by FDG-PET
    Sokler, M
    Dohmen, BM
    Bokemeyer, C
    Brugger, W
    Kopp, A
    Bares, R
    Kanz, L
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1189 - 1189
  • [4] Cavitary lung cancer and FDG-PET
    Triponez, F
    de Perrot, M
    Orrit, J
    Robert, J
    Spiliopoulos, A
    ANNALES DE CHIRURGIE, 2002, 127 (05): : 403 - 404
  • [5] PRECISION OF REPEATED QUANTITATIVE FDG-PET SCANS IN PATIENTS WITH UNTREATED LUNG-CANCER
    MINN, HRI
    ZASADNY, KR
    QUINT, LE
    WAHL, RL
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P75 - P75
  • [6] Clinical utility and limitation of FDG-PET in detecting recurrent HCC
    Hayakawa, Nobuyuki
    Nakamoto, Yuji
    Higashi, Tatsuya
    Togashi, Kaori
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [7] Impact of FDG-PET in patients with biochemical evidence of recurrent or residual medullary thyroid cancer
    J. T. Plukker
    J. W. De Groot
    T. P. Links
    P. L. Jager
    Annals of Surgical Oncology, 2004, 11 : S105 - S105
  • [8] FDG-PET/CT in assessment of residual or recurrent head and neck cancer after chemoradiotherapy
    Garcia-Velloso, M. J.
    Vigil, C.
    Alcalde, J.
    Dominguez, I.
    Moreno, M.
    Lopez-Picazo, J.
    Richter, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S409 - S409
  • [9] Impact of FDG-PET in patients with biochemical evidence of recurrent or residual medullary thyroid cancer
    Plukker, JT
    De Groot, JW
    Links, TP
    Jager, PL
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : S105 - S105
  • [10] Interest of FDG-PET for lung cancer radiotherapy
    Thureau, S.
    Mezzani-Saillard, S.
    Modzelewski, R.
    Edet-Sanson, A.
    Dubray, B.
    Vera, P.
    CANCER RADIOTHERAPIE, 2011, 15 (6-7): : 504 - 508